- Conditions
- Gout
- Interventions
- DYV700, Placebo, Colchicine 0.6 mg
- Drug
- Lead sponsor
- Dyve Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Poway, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 48
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gout
- Interventions
- Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone
- Biological · Drug · Dietary Supplement
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more
- Conditions
- Gout
- Interventions
- High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
- Conditions
- Gout
- Interventions
- Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 49 more
- Conditions
- Coronary Artery Disease
- Interventions
- Methotrexate, Colchicine, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Gout, Chronic Kidney Disease (CKD)
- Interventions
- Lesinurad, XOI, Placebo, colchicine, corticosteroids
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
- Conditions
- Coronary Artery Disease
- Interventions
- Colchicine, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Long Beach, California • Gainesville, Florida + 6 more
- Conditions
- Coronary Artery Disease
- Interventions
- Rosuvastatin, Colchicine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hyperuricemia, Gout
- Interventions
- Arhalofenate, Placebo comparator, Colchicine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 9 more
- Conditions
- Statin Adverse Reaction
- Interventions
- Low-dose colchicine at 0.5mg daily, Placebo
- Drug · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Neutrophils.Hypersegmented | Bld-Ser-Plas, STEMI - ST Elevation Myocardial Infarction
- Interventions
- Colchicine Pill
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 19 Years to 110 Years
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
- Interventions
- Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
- Drug · Device
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Intercritical Gout
- Interventions
- Colchicine (Colcrys®), placebo, allopurinol
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 37
- States / cities
- Alabaster, Alabama • Mesa, Arizona • Upland, California + 34 more
- Conditions
- Acute Gout
- Interventions
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 96
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
- Conditions
- Pharmacokinetics
- Interventions
- Norethindrone/Ethinyl Estradiol, Colchicine, Placebo (for Colchicine)
- Drug
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Corona Virus Infection
- Interventions
- Colchicine, Placebo oral tablet
- Drug
- Lead sponsor
- Montreal Heart Institute
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 4,506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Yuma, Arizona • Bakersfield, California + 12 more
- Conditions
- Gout
- Interventions
- SAP-001
- Drug
- Lead sponsor
- Shanton Pharma Pte. Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 15
- States / cities
- Sacramento, California • San Diego, California • Denver, Colorado + 11 more
- Conditions
- Peripheral Artery Disease
- Interventions
- Colchicine, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
- Interventions
- Active Colchicine, Active Placebo
- Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 3,209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- Weston, Florida • Detroit, Michigan • Stony Brook, New York + 5 more
- Conditions
- Radiation Therapy
- Interventions
- oral colchicine(0.6 mg) once a day
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Livingston, New Jersey • New Brunswick, New Jersey
- Conditions
- Obesity, Metabolic Disease
- Interventions
- Colchicine 0.6Mg Cap, Placebo capsules given, Colchicine 0.6Mg Tab
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atrial Fibrillation
- Interventions
- Colchicine 0.6 mg, Placebo
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Gout
- Interventions
- Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 192
- States / cities
- Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
- Conditions
- Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
- Interventions
- ABP-745 Dose A, ABP-745 Dose B, Colchicine, Placebo
- Drug
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Peoria, Arizona • La Mesa, California • Norcross, Georgia + 11 more